Treatment of post-menopausal women with oestrogen-receptor-positive, locally advanced or metastatic breast cancer

250 mg monthly

Molecular weight :606.8

%Protein binding :99

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :3–5

half-life – normal/ESRD (hrs) :40 days/unchanged

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

Potentially hazardous interactions with other drugs

None known

–

–

–

As it is an intramuscular injection, use with caution in patients who are heparinised.